FOXO4-DRIvsNAD+

FOXO4-DRI is a D-retro-inverso (DRI) peptide — a peptide composed entirely of D-amino acids (mirror image of natural L-amino acids) assembled in reverse sequence order. This DRI modification makes the peptide virtually invisible to cellular proteases (which have evolved to cleave L-amino acid peptide bonds), dramatically extending its biological half-life while preserving the spatial orientation of key amino acid side chains needed for target interaction.

The target is the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Cellular senescence is a state of permanent cell cycle arrest triggered by DNA damage, oncogene activation, or telomere shortening. Senescent cells would normally undergo p53-mediated apoptosis (programmed cell death), but they evade this fate through a survival mechanism: the transcription factor FOXO4 is selectively upregulated in senescent cells and physically binds to p53, sequestering it in PML (promyelocytic leukemia) nuclear bodies. This binding prevents p53 from activating its pro-apoptotic transcriptional program (PUMA, BAX, NOXA), keeping the damaged cell alive.

FOXO4-DRI competitively disrupts this interaction by mimicking the FOXO4 binding interface for p53 but without the nuclear body-localizing function. When FOXO4-DRI competes p53 away from endogenous FOXO4, liberated p53 can access its apoptotic target genes, triggering mitochondrial outer membrane permeabilization and caspase activation — selectively killing the senescent cell. Crucially, non-senescent cells do not depend on FOXO4-p53 interaction for survival (they have intact cell cycle regulation and don't upregulate FOXO4), so they are unaffected by FOXO4-DRI. This selectivity — killing only 'zombie' senescent cells while sparing healthy cells — makes FOXO4-DRI a true senolytic agent. In the original 2017 Cell publication by de Keizer et al., FOXO4-DRI treatment in aged mice reduced senescent cell burden and restored physical fitness, fur density, and renal function.

Nicotinamide Adenine Dinucleotide (NAD+) is a dinucleotide coenzyme consisting of nicotinamide mononucleotide (NMN) joined to adenosine monophosphate (AMP) through a pyrophosphate bond. It exists in oxidized (NAD+) and reduced (NADH) forms and participates in over 500 enzymatic reactions, making it one of the most central molecules in cellular metabolism.

As a redox cofactor, NAD+ accepts hydride ions (H-) during catabolic reactions. In glycolysis, the TCA cycle, and fatty acid beta-oxidation, NAD+ is reduced to NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving oxidative phosphorylation and ATP production. Without adequate NAD+, the entire energy production machinery of the cell grinds to a halt.

Equally important are NAD+'s roles as a consumed substrate for three families of signaling enzymes. Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases and ADP-ribosyltransferases that use NAD+ as a co-substrate, cleaving it to nicotinamide and O-acetyl-ADP-ribose during the deacetylation reaction. SIRT1 and SIRT3 are particularly important for aging — SIRT1 deacetylates PGC-1α (activating mitochondrial biogenesis), FOXO transcription factors (activating stress resistance), and NF-κB (suppressing inflammation). SIRT3 in the mitochondrial matrix activates SOD2 and other mitochondrial enzymes. PARPs (poly-ADP-ribose polymerases) consume NAD+ during DNA damage repair, adding chains of ADP-ribose to histones near DNA breaks to recruit repair machinery. CD38, an NAD+-consuming glycohydrolase on immune cells, regulates calcium signaling and immune activation.

NAD+ levels decline 40-60% between ages 40 and 70, driven by increased CD38 expression (with chronic low-grade inflammation), increased PARP activity (from accumulated DNA damage), and reduced synthesis (decreased NAMPT enzyme activity). This decline impairs sirtuin function, reduces ATP production, compromises DNA repair, and contributes to virtually every hallmark of aging. Supplementation strategies aim to restore NAD+ levels either directly (IV infusion) or through biosynthetic precursors: NMN enters the salvage pathway one step from NAD+, while NR (nicotinamide riboside) requires an additional phosphorylation step.